Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2442:635-653.
doi: 10.1007/978-1-0716-2055-7_34.

Untangling Galectin-Mediated Circuits that Control Hypoxia-Driven Angiogenesis

Affiliations

Untangling Galectin-Mediated Circuits that Control Hypoxia-Driven Angiogenesis

Nadia Bannoud et al. Methods Mol Biol. 2022.

Abstract

Development of an aberrant vascular network is a hallmark of the multistep pathological process of tumor growth and metastasis. In response to hypoxia, several pro-angiogenic factors are synthesized to support vascularization programs required for cancer progression. Emerging data indicate the involvement of glycans and glycan-binding proteins as critical regulators of vascular circuits in health and disease. Galectins may be regulated by hypoxic conditions and control angiogenesis in different physiopathological settings. These β-galactoside-binding proteins may promote sprouting angiogenesis by interacting with different glycosylated receptors and triggering distinct signaling pathways. Understanding the role of galectins in tumor neovascularization will contribute to the design of novel anti-angiogenic therapies aimed at complementing current anti-cancer modalities and overcoming resistance to these treatments. Here we describe selected strategies and methods used to study the role of hypoxia-regulated galectins in the regulation of blood vessel formation.

Keywords: Angiogenesis; Galectins; Hypoxia.

PubMed Disclaimer

References

    1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257 - DOI
    1. Martin JD, Seano G, Jain RK (2019) Normalizing function of tumor vessels: Progress, opportunities, and challenges. Annu Rev Physiol 81:505–534 - DOI
    1. Motz GT, Coukos G (2011) The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11:702–711 - DOI
    1. Croci DO, Mendez-Huergo SP, Cerliani JP et al (2018) Immune-mediated and hypoxia-regulated programs: accomplices in resistance to anti-angiogenic therapies. Handb Exp Pharmacol 249:31–61 - DOI
    1. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364 - DOI

MeSH terms

LinkOut - more resources